Amneal Pharmaceuticals (AMRX)
(Delayed Data from NSDQ)
$8.38 USD
+0.33 (4.10%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.38 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Amneal Pharmaceuticals (AMRX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$9.25 | $10.00 | $8.00 | 14.91% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Amneal Pharmaceuticals comes to $9.25. The forecasts range from a low of $8.00 to a high of $10.00. The average price target represents an increase of 14.91% from the last closing price of $8.05.
Analyst Price Targets (4 )
Broker Rating
Amneal Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.80 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.80 a month ago based on five recommendations.
Of the five recommendations deriving the current ABR, four are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 80%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/AMRX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.80 | 1.80 | 1.80 | 1.80 | 1.80 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | Truist Securities | Leszek Sulewski | Strong Buy | Strong Buy |
6/20/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
3/4/2024 | Goldman Sachs | Nathan Rich | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.80 |
ABR (Last week) | 1.80 |
# of Recs in ABR | 5 |
Average Target Price | $9.25 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 96 of 253 |
Current Quarter EPS Est: | 0.13 |